Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor

Prostaglandins
G C KaneS P Peters

Abstract

We have recently reported that the 5-lipoxygenase (5-LO) inhibitor, zileuton, alters lung inflammation produced by segmental antigen challenge in ragweed-allergic human subjects. Specifically, zileuton inhibited the urinary excretion of leukotriene E4 produced by antigen challenge, and the significant increase in bronchoalveolar lavage (BAL) eosinophils observed in subjects on placebo was not seen in subjects on zileuton. In this manuscript, we report additional data obtained during that study which provide information about mechanisms important during IgE-mediated inflammatory reactions in the lung. Three different areas are addressed: 1) the time to recovery of the lung from an IgE-mediated inflammatory response; 2) mechanisms related to the generation of cyclooxygenase products in the lung after antigen challenge and the effect of 5-LO inhibition on the production of cyclooxygenase metabolites; and 3) mechanisms responsible for the production of peptide leukotrienes in the lung and lung injury (as shown by albumin influx into the alveolar air space) 24 h after antigen challenge. We observed the following: 1) a significant BAL eosinophilia and basophilia remained 31 days (range 21-48) after segmental antigen challenge and bro...Continue Reading

References

Jun 1, 1990·The American Review of Respiratory Disease·K SladekJ R Sheller
Jan 1, 1989·The American Review of Respiratory Disease·R DworskiG A Fitzgerald
Jul 11, 1985·The New England Journal of Medicine·R M NaclerioL M Lichtenstein
Feb 1, 1987·Archives of Otolaryngology--head & Neck Surgery·M S BrownR M Naclerio
Sep 25, 1986·The New England Journal of Medicine·J J MurrayJ A Oates
Apr 1, 1984·The Journal of Clinical Investigation·R A Lewis, K F Austen
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·P F WellerR A Lewis
Sep 1, 1982·Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology·E S SchulmanH H Newball
Oct 1, 1982·The Journal of Clinical Investigation·D W MacGlashanL M Lichtenstein
Apr 1, 1994·American Journal of Respiratory Cell and Molecular Biology·C B GuoL M Lichtenstein
Apr 1, 1994·American Journal of Respiratory and Critical Care Medicine·R DworskiJ R Sheller
Mar 1, 1993·The American Review of Respiratory Disease·D S CollinsS P Peters

❮ Previous
Next ❯

Citations

Feb 8, 2008·Archives of Pharmacal Research·Chan Hun JungChang Jong Kim
May 29, 1998·The New England Journal of Medicine·M E Rothenberg
Mar 31, 2007·International Journal of Clinical Practice·W BergerC B Cairns
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·S T Holgate, A P Sampson
Mar 3, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S E Wenzel
May 5, 2001·Expert Opinion on Pharmacotherapy·L García-Marcos, A Schuster
May 18, 2013·Cancer Prevention Research·Arash MohebatiAndrew J Dannenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.